| Mrs Linda B Eagle, OTRL | |
|
101 Bogie Hills Dr, Columbia, MO 65201-2832 | |
| (573) 999-4925 | |
| (573) 443-2075 |
| Full Name | Mrs Linda B Eagle |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 101 Bogie Hills Dr, Columbia, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013061423 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 003704 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Linda B Eagle, OTRL 101 Bogie Hills Dr, Columbia, MO 65201-2832 Ph: (573) 999-4925 | Mrs Linda B Eagle, OTRL 101 Bogie Hills Dr, Columbia, MO 65201-2832 Ph: (573) 999-4925 |
News Archive
Behavioral Innovations, the premier Dallas/Fort Worth provider of Applied Behavior Analysis (ABA) services for families of children with autism and other developmental disorders, announces its partnership with key insurance carriers to offer in-network insurance coverage for several ABA therapy programs. Behavioral Innovations is the first behavioral therapy center in the Metroplex to offer in-network insurance for select treatments - mitigating the financial burden on parents.
We have tended to associate welfare technology with support for the elderly. Now researchers are looking at whether technology such as digital calendars and smartwatches can also provide support for children with autism and ADHD.
Understanding the effects of age and disease on sexual wellbeing is crucial as sexual health is increasingly associated with vitality. In a new study published in The American Journal of Medicine, researchers looked at the role metabolic syndrome and cardiovascular disease play in postmenopausal women's sexual health.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths. Deferoxamine Mesylate is therapeutically equivalent to the reference-listed drug Desferal®, which is marketed by the innovator Novartis.
› Verified 2 days ago
Robin Elizabeth Howard-boyd, MOT, OTR/L, CHT Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 3301 Berrywood Dr, Columbia, MO 65201 Phone: 573-449-8771 | |
Jonalyn Marie Siemer, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 103 Anderson Ave, Columbia, MO 65203 Phone: 573-443-8494 | |
Bonnie Schuett, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4812 Santana Cir, Columbia, MO 65203 Phone: 573-514-3525 | |
Mrs. Kimberly Mae Hickey, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6000 | |
Kathryn Elizabeth Stukel, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6000 | |
Brianna Kim, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 104 Granada Blvd Apt A, Columbia, MO 65203 Phone: 720-935-1077 |